Medical representative norms, AstraZeneca, Hebei Hospital, Celine Dion, and pharmaceutical mergers and acquisitions are the key words in the near future.
yearsmonthOn Sunday, Shaanxi Province promulgated the "Regulations on the Management of the Reception of Medical Representatives in Medical Institutions (Trial)", which clarified the process specifications for medical representatives in hospitals, which stipulates that if the staff of medical institutions receive medical representatives without authorization, the staff involved and the heads of relevant departments (departments) shall be interviewed by the unit. where the circumstances are serious, the unit to which they belong or the competent department at the level above is to handle it.
Prior to this, Jiangxi, Hebei and other places have also issued relevant documents to clarify the hospital's reception specifications for medical representatives. In the past, relevant rules and regulations were issued for each hospital to standardize the academic promotion work of medical representatives in hospitals from the provincial level, which means greater supervision
The "Notice on Regulating the Reception of Medical Representatives by Staff of Medical Institutions" issued by Hebei Province requires that medical representatives should make an appointment in advance if they want to enter medical institutions to engage in related work, and the staff of medical institutions shall not contact medical representatives in violation of regulations and privately, and shall not provide medical representatives with the number of front-line staff using enterprise products in any way. In addition, medical institutions should carry out inspections from time to time, and if it is found that medical representatives are carrying out activities at non-specified times and places, they should immediately persuade them to leave and retain evidence.
As early as the beginning of 2022, the Jiangxi Provincial Health Commission issued the "Notice on Printing and Distributing the Administrative Measures for Visiting Staff in Medical Representative Medical Institutions" (hereinafter referred to as the "Measures"), which is regarded as the first provincial-level management method for medical representative visits.
The measures stipulate that medical institutions should establish a reception day management system, implement appointment reception, and the hospital medical ethics department is responsible for organizing and implementing it, and the relevant functional departments jointly implement it, and receive it in accordance with the principle of "three fixed and two haves" (fixed reception time, fixed reception location, fixed reception personnel, reception process, and reception record);Medical representatives can only carry out academic promotion and commercial promotion activities in medical institutions on reception days, and if special circumstances require them to engage in the above activities in medical institutions on non-reception days, they can only be carried out after approval by the medical ethics and medical style department of the medical institutionWithout permission, medical representatives are not allowed to conduct business activities in medical institutions. It is strictly forbidden for the staff of medical institutions to violate the relevant regulations on reception management and contact with medical representatives in medical institutions without authorization.
yearsmonthOn Sunday, the Hebei Provincial Health Commission issued a notice on the establishment of the Langfang Campus of the Cancer Hospital of the Chinese Academy of Medical SciencesHereinafter referred to asLangfang CampusThe information shows that the nature of the hospital's operation is non-profit.
In the above-mentioned announcement, the Hebei Provincial Health Commission stated that after research and demonstration of the application materials submitted by the Cancer Hospital of the Chinese Academy of Medical Sciences, it is proposed to agree to set up the Langfang Campus of the Cancer Hospital of the Chinese Academy of Medical Sciences as a non-independent legal person.
Langfang Hospital is classified as a ** specialized hospital, located at No. 67 Huayuan Road, Langfang Economic and Technological Development Zone. According to China News NetworkReportThe address is exactlyHebei Hospital, the Cancer Hospital of the Chinese Academy of Medical Sciences, which previously caused controversyAbbreviationHebei HospitalAddress.
According to the previous approval of the Hebei Provincial Health Commission three years ago, this Hebei hospital is a non-profit hospital jointly established by the Cancer Hospital of the Chinese Academy of Medical Sciences and MCC Jixin Health Industry Co., Ltd., which is a social medical institution.
On August 9, 2023, "Hebei Youth Daily" published a very small announcement on the cancellation of "tofu blocks", which attracted ** attention. According to the announcement, the Cancer Hospital of Hebei Chinese Academy of Medical Sciences, located in Langfang Campus, intends to apply for cancellation of registration with the organization registration management authority.
The "Hebei Hospital" project began to be approved in 2019, and in May of the same year, the Langfang Economic and Technological Development Zone Management Committee, the Cancer Hospital of the Chinese Academy of Medical Sciences, and China Metallurgical Science and Industry Co., Ltd. completed the signing in Beijing, and officially started construction in 2020, positioning it as a first-class cancer hospital, with a total investment of 94600 million yuan, which is planned to be completed and put into use in 2024.
On January 10, 2019, a report titled "Langfang Municipal Health Commission Escorts People's Health" proposed for the first time to "speed up the preliminary work of Langfang Central Hospital and promote the implementation of Beijing Cancer Hospital Langfang Campus as soon as possible".
Since then, the people of Langfang City have publicly disclosed that the Langfang Branch of Beijing Cancer Hospital of the Chinese Academy of Medical Sciences has determined the site.
On February 2, 2019, the signing ceremony of the Langfang Campus of the Cancer Hospital of the Chinese Academy of Medical Sciences was held in Langfang City, and Chen Ping, then Deputy Secretary of the Langfang Municipal Party Committee and Mayor, and He Jie, President of the Cancer Hospital of the Chinese Academy of Medical Sciences, completed the signing on behalf of both parties.
According to Hebei News Network, on January 21, 2020, the project commencement promotion meeting of the Langfang Campus of the Cancer Hospital of the Chinese Academy of Medical Sciences was held in Langfang Development Zone. Lin Qiuhong, then director of the Economic Development Bureau of Langfang Development Zone, introduced: "The project of Langfang Campus of the Cancer Hospital of the Chinese Academy of Medical Sciences is positioned as a first-class cancer hospital. The total investment of the project is 94600 million yuan, of which 87 million was invested in the Langfang branch of the cancer hospital600 million yuan, and the National Cancer Center invested 700 million yuan. A total of 2,600 beds are designed. ”
yearsmonthOn the day, the Hebei Provincial Health Commission issued the "Announcement on the Establishment of Hebei Hospital, a Cancer Hospital of the Chinese Academy of Medical Sciences".In order to further promote the coordinated development of medical and health care in Beijing, Tianjin and Hebei, in accordance with the relevant regulations on the management of medical institutions, it is proposed to agree to set up Hebei Hospital, a cancer hospital of the Chinese Academy of Medical Sciences, after research and demonstration.
Different from the previous public information, in the content of this announcement, the name of the medical institution is: Hebei Hospital, Cancer Hospital of the Chinese Academy of Medical Sciences, which belongs to the first specialized hospital;It is set up in the Cancer Hospital of the Chinese Academy of Medical SciencesMCC Jixin HealthIndustrial Limited Liability Company;Beds.
After the above announcement, on November 24, 2020, the Hebei Provincial Health Commission sent a letter to the Langfang Municipal Health Commission: agreeing to the Cancer Hospital of the Chinese Academy of Medical Sciences and MCC Jixin Health Industry Co., Ltd. to jointly establish the Hebei Hospital of the Cancer Hospital of the Chinese Academy of Medical Sciences.
According to the National Social Organization Credit Information Publicity Platform, the Cancer Hospital of the Chinese Academy of Medical Sciences in Hebei Province is a private non-enterprise unit, and the Ministry of Civil Affairs handled the "Registration Certificate for Private Non-enterprise Units" for the unit on November 5, 2021.
On December 22, 2022, the official website of the Cancer Hospital of the Chinese Academy of Medical Sciences issued the "Announcement on the Labor Dispatch Service Procurement Project of Hebei Hospital", which intends to purchase the labor dispatch service project of Hebei Hospital.
Recently, the sister of the 55-year-old internationally famous singer Celine Dion revealed in an interview with ** that Celine Dion"The condition worsened and I couldn't control my laryngeal muscles. What breaks my heart is that she has always followed the doctor's advice and she has been working very hard. Now we don't seem to see hope. There is no specific drug for this disease, it is impossible to **, and she still struggles with a rare neurological disorder. ”
Since November 2022, Celine Dion has been rumored many times that she suddenly canceled her 21 concert tours due to health problems, and it was rumored that she was almost paralyzed, making fans very worried about her physical condition.
yearsmonthday, Celine Dion passedNetwork**published a video to confirm to fans that he was suffering from a rare neurological disease "stiff person syndrome" (stiff person syndromeThe disease is the cause of her constant cramps, in addition to causing mobility problems, it also makes it impossible for her to sing smoothly with her vocal cords, so she canceled the 2023 concert altogether.
Stiff-person syndrome, also known as zombie syndrome or zombie syndrome (stiff person syndromeorstiff man syndrome), is a rare and disabling autoimmune disease, **unknown, and the patient's clinical manifestations gradually begin to become stiff, muscle rigidity, etc. It can cause some patients to develop a hunched back and be unable to walk unaided.
Stiff man syndrome was first described in 1956 as "stiff man syndrome", in which the main clinical manifestations of patients are gradual stiffness of the neck, shoulders and upper back, as well as paroxysmal painful muscle spasms and difficulty walking. Subsequent observations found that there were both men and women, so it was renamed Stiff Person Syndrome (SPS). Because many of these patients have other autoimmune diseases, the immune mechanism of this disease has gradually been emphasized.
Approximately 1 in 1 million people is affected, and the incidence in women is twice as high as in men. It is understood that more than 1,000 cases have been admitted to the country.
yearsmonthAstraZeneca, a multinational pharmaceutical company, announced that it has made an announcement on Gracell Biotechnology Group (NASDAQ***grcl；Gracell Biosciences signed a definitive agreement for the acquisition proposal to further deepen AstraZeneca's layout in the field of cells. Gracell will continue to operate in China and the U.S. as a wholly owned subsidiary of AstraZeneca. Grabid Biotech's U.S. stocks rose more than in pre-market trading, newspaperDollar.
Gracell Biosciences is a global, clinical-stage biopharmaceutical company dedicated to the development of innovative cells for oncology and autoimmune diseases.
Under the terms of the definitive agreement, AstraZeneca will merge and acquire all of Gracell's diluted shares, including all ADS-represented shares. AstraZeneca will receive cash per share of its common shares (the "Common Shares") at closing**200 USD (equivalent to ADS 10 per share.)00 USD) to complete the acquisition. In addition, a non-tradable contingent interest is attached to the terms under which AstraZeneca will pay 0.0 per ordinary share in cash upon the achievement of certain regulatory-related milestones$3 (equivalent to $1 per ADS.)$5).
The cash down payment portion of the transaction consideration was valued at approximately $1 billion, representing a 62% premium to Grabar's ** price on December 22, 2023, and a 60-day volume-weighted average** (VWAP) prior to the announcement3$94 premium of 154%. If this upfront payment and potential contingent value payments go through, the combined transaction value would be approximately $1.2 billion, representing an 86% premium to Gracell's ** price on December 22, 2023 and a 192% premium to the 60-day VWAP. As part of the proposed transaction, AstraZeneca will receive the remaining cash, cash equivalents and short-term investments on Gracella's balance sheet. As of September 30, 2023, Gracell had total cash, cash equivalents and short-term investments of 2$34.1 billion.
The transaction is expected to close in the first quarter of 2024, subject to customary closing conditions, including regulatory approvals, as well as approvals from Gracell Biotech's shareholders.
yearsmonthDay, Bristol-Myers Squibb (bmsAnnounced$100 million acquisition of a brain drug manufacturerkaruna, successfully ranked among the second highest value pharmaceutical mergers and acquisitions in the year. bmsIt is also the record holder for the largest M&A in the pharmaceutical industryyears$100 million to buy an antibody drug manufacturercelgene
This year is a big year for mergers and acquisitions in the pharmaceutical industry. According to the medical Rubik's Cube,As ofmonthday, this year the pharmaceutical industry sharedSectMergers and acquisitions of more than 100 million US dollars, if you include AstraZeneca's acquisition of Gracell Biologics, this figure reachesSectThe largest of themThe total amount of the parcel is reachedbillion dollars, higher than last year'sbillion dollars.
According to incomplete statistics from Fierce Biotech, there have been at least 70 mergers and acquisitions in the pharmaceutical industry this year. For example, Pardes was acquired in July this year due to unsatisfactory data from the second phase of the new crown drug pomotrelvir.
The woes for small pharma began last year, but at the time of macroeconomic volatility, big pharma was cautious about acquisitions, or thought valuations had not fallen low enough. Despite tens of billions of dollars in mergers and acquisitions, PwC said 2022 was a "challenging" year.
M&A has made a significant comeback this year, and in the words of Bruce Booth, a partner at venture capital Atlas, "to my knowledge, this is an all-time high for biotech M&A in the public market......We expect the pace of M&A to likely accelerate in 2024."
Japan's high-end medical 2023 sprint equipment R&D and production base settled in Pinghu, Zhejiang.
According to the Pinghu Municipal Bureau of Commerce of Zhejiang Province,yearsmonthDay, JapanfandfThe high-end medical equipment project of Co., Ltd. was officially signed in Pinghu. The total investment of the projectUS$10,000 (equivalent to RMB100 million yuan), of which the total investment in the first phase$10,000, landacres, will build oneR&D and production base of more than 10,000
According to the data, Japan's FANDF Co., Ltd. mainly produces and sells core electronic components of high-end medical instruments and equipment such as CT, MR, ultrasound diagnostic equipment, CT scanning, angiography, etc., and its main customers are GE Medical, Siemens Healthineers, Canon, Hitachi, Konica Minolta, Fujifilm and other well-known enterprises. It is worth mentioning that this project mainly provides related product supporting services for medical imaging giant GE Healthcare. It is expected that the project will be put into operation in 2025, and the annual output value is expected to exceed 300 million yuan within five years.
In recent years, with the continuous development of medical imaging equipment technology, the introduction of related products and the update and iteration of product performance, the efficiency and accuracy of medical imaging equipment diagnosis have been continuously improved, the demand for imaging equipment for clinical diagnosis has been growing, and the integration of medical imaging equipment and emerging technologies has become an important driving force for the innovation and upgrading of global medical imaging equipment.
RootsAccording toData from Frost & SullivanThe global medical imaging equipment market size is expected to reach the annual market sizebillion dollars. CompareyearsThere was a large increase of 100 million US dollars. The growth is mainly driven by the increasing demand for medical equipment, the aging population, and other factors. It is estimated that the global medical imaging equipment market size will reach 607700 million US dollars, with a compound growth rate of 55%。